



An Independent Licensee of the Blue Cross and Blue Shield Association

**Date:** February 2, 2026

**To:** FHCP Contracted Primary Care Providers, Specialists and FHCP Staff Providers  
**From:** FHCP Pharmacy Services  
**Re:** January 2026 Pharmacy News

Attached please find the January 2026 Pharmacy News.

For additional information regarding Florida Health Care Plans' formularies please visit [fhcp.com](http://fhcp.com) or [FHCPMedicare.com](http://FHCPMedicare.com)

If there are any questions regarding this announcement, please contact the Florida Health Care Plans Pharmacy Help Desk at 888.676.7173



An Independent Licensee of the Blue Cross and Blue Shield Association

## PHARMACY NEWS 01-14-2026

**TO: MEDICAL and PHARMACY STAFF**  
**FROM: PHARMACY SERVICES**

---

The FHCP Pharmacy and Therapeutic Committee reviewed the following therapeutic classes of drugs at its last meeting held December 9th 2025: Genitourinary Smooth Muscle Relaxants, Pulmonary Smooth Muscle Relaxants Vitamins (B Complex, D Vitamins, Multi-Vitamins, Misc Vitamins), Unclassified Therapeutic Agents, Pulmonary Anti-Inflammatory Agents (non-steroidal), Devices, Bone Density Enhancers, Transplant Agents, Injectables and Biologics, Hematopoietics

---

### **Formulary Changes**

#### **Formulary Additions**

- **Inluriyo (imlunestrant)** - Tier 5 PA Medicare only
- **Hyrnuo® (sevabertinib)** - Tier 5 PA Medicare only
- Praculopride (Generic Motegrity)- Tier 2 all lines of business (FHCP only - commercial/ACA)
- Ferric Citrate (Generic Auryxia)- Tier 2 all lines of business

#### **Formulary Deletions:** -

N/A

---

### **Part D Star Measure - Concurrent Use of Opioids and Benzodiazepines (COB)**

- The percentage of individuals  $\geq 18$  years with concurrent use of prescription opioids and benzodiazepines for  $\geq 30$  cumulative days. (Excludes patients in hospice or palliative care and those with cancer or sickle cell disease.) This includes all benzo classes, it excludes “Z” drugs (zolpidem, zaleplon, eszopiclone)
- FHCP is underperforming in this quality measure with a rate of members on this drug combination that is twice the national average. Please evaluate your patients for opportunities to de-prescribe. Prescribers of this combination will receive a list of their patients in the coming weeks. FHCP Addiction Medicine providers will also be offering support for safe de-prescribing along with education on tapering and alternative regimens. More information on this will be coming soon.

THANKS!